Page last updated: 2024-08-23

selegiline and Basal Ganglia Diseases

selegiline has been researched along with Basal Ganglia Diseases in 5 studies

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (20.00)	18.7374
1990's	3 (60.00)	18.2507
2000's	1 (20.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hollán, S; Magyar, K; Vécsei, L	1
Bodkin, JA; Cannon, SE; Cohen, BM; Cole, JO; Salomon, MS; Zornberg, GL	1
Góraj, B; Kleinert, A; Sińczuk-Walczak, H	1
Ghaemi, M; Rudolf, J; Schmülling, S	1
Defazio, G; Ferrari, E; Lamberti, P; Lepore, V; Livrea, P	1

Trials

1 trial(s) available for selegiline and Basal Ganglia Diseases

Article	Year
Treatment of negative symptoms in schizophrenia and schizoaffective disorder by selegiline augmentation of antipsychotic medication. A pilot study examining the role of dopamine. The Journal of nervous and mental disease, 1996, Volume: 184, Issue:5 Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Depressive Disorder; Dopamine; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Pilot Projects; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology; Selegiline; Severity of Illness Index	1996

Article

Year

Treatment of negative symptoms in schizophrenia and schizoaffective disorder by selegiline augmentation of antipsychotic medication. A pilot study examining the role of dopamine.

The Journal of nervous and mental disease, 1996, Volume: 184, Issue:5

Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Depressive Disorder; Dopamine; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Pilot Projects; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology; Selegiline; Severity of Illness Index

1996

Other Studies

4 other study(ies) available for selegiline and Basal Ganglia Diseases

Article	Year
Adverse effects of dopamine potentiation by long-term treatment with selegiline. Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:1 Topics: Adolescent; Adult; Anemia, Hemolytic, Congenital; Antiparkinson Agents; Baclofen; Basal Ganglia; Basal Ganglia Diseases; Blood Platelets; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Dystonia Musculorum Deformans; Female; Genetic Carrier Screening; Genotype; Glyceraldehyde-3-Phosphate Dehydrogenases; Humans; Huntingtin Protein; Long-Term Care; Male; Middle Aged; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nerve Tissue Proteins; Neurologic Examination; Neuroprotective Agents; Nuclear Proteins; Polymerase Chain Reaction; Proteins; Psychoses, Substance-Induced; Reference Values; Selegiline; Trinucleotide Repeats	2004
[Acute poisoning by carbon monoxide affecting the extrapyramidal system]. Medycyna pracy, 1998, Volume: 49, Issue:6 Topics: Acute Disease; Adult; Basal Ganglia Diseases; Brain; Carbon Monoxide Poisoning; Female; Humans; Magnetic Resonance Imaging; Neuroprotective Agents; Selegiline	1998
Deterioration of parkinsonian symptoms following treatment of dopaminergic hallucinosis with olanzapine. European psychiatry : the journal of the Association of European Psychiatrists, 1999, Volume: 14, Issue:6 Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Drug Therapy, Combination; Hallucinations; Humans; Levodopa; Male; Olanzapine; Paranoid Disorders; Parkinson Disease; Piperidines; Pirenzepine; Selegiline; Severity of Illness Index	1999
Facial dystonia: clinical features, prognosis and pharmacology in 31 patients. Italian journal of neurological sciences, 1989, Volume: 10, Issue:6 Topics: Adult; Aged; Basal Ganglia Diseases; Botulinum Toxins; Drug Combinations; Female; Haloperidol; Humans; Levodopa; Male; Meige Syndrome; Middle Aged; Phenethylamines; Prognosis; Selegiline	1989